Faculty Opinions Recommendation of Association Between 5-Alpha Reductase Inhibition and Risk of Hip Fracture

    John K. Amory
    TLDR 5-alpha reductase inhibitors do not increase hip fracture risk.
    Jacobsen and colleagues conducted a case-control study using the Kaiser database to investigate the association between hip fracture risk and the use of 5-alpha-reductase inhibitors in men. The study found that these inhibitors, which prevent the conversion of testosterone to dihydrotestosterone (DHT), did not increase the risk of hip fractures and may actually decrease it. This finding was significant as many older men use these medications for prostate hypertrophy and cancer prevention. The study also suggested that DHT likely did not play a role in maintaining bone mineral density in men, and the slight increase in testosterone from these medications could be beneficial.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Wtf have we been doing for the last 30 years

      in Treatment  548 upvotes 11 months ago
      Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

      community Update: 4 Month progress on Fin/Min plus dermaroller

      in Progress Pictures  559 upvotes 1 year ago
      A user shared a 4-month update on their hair regrowth progress using finasteride, minoxidil, a dermaroller, ketoconazole shampoo, multivitamins, and biotin, and received positive reactions and inquiries from others. They also mentioned lifestyle changes such as quitting creatine, alcohol, and smoking, which may have contributed to their success.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    4 / 4 results